Utilisateur:Genbiotech SAS/Brouillon
GENBIOTECH, a previously Biotechnology department of Laboratoires Genévrier background includes 15 years of strategic involvement in R&D in the field of rheumatology, dermatology and gynecology where mains treatments are still non-satisfactory. GENBIOTECH aims to improve existing treatments by using non-invasives processes allowing local sustained administration of biological and active molecules. GENBIOTECH is distinguished by its rental offer clean rooms, its innovative production plant and development of Cell Engineering products.
GENBIOTECH believes that tomorrow medicine needs to be dedicated and targeted to patients Our goal is then to bring innovative solutions for revolutionizing biological drug administration to treat pathologies which are still unsatisfied. Our products strength includes, reducing patient risk for severe side effects such as invasive surgery in diabetes, avoiding massive administration of drugs such as corticosteroids in musculoskeletal diseases, increasing treatment efficacy and physician practices.
GENBIOTECH assets intend
- a comprehensible and pragmatic activities within the actual scope of public health
- a Board of directors highly experienced with development and industrialization of biotechnology projects [i.e. Endocell (patent #05809271.9), Viticell (Patent #1255333)]
- a Board of directors highly experienced with commercial launches (i.e. penetration and market knowledge, historical network of distributors)
- an already established scientific network Certification ISO9001, ISO13485, ISO14001.
GENBIOTECH employs 9 people in the 1st January 2014.
Cluster member EUROBIOMED
Actor cluster Perfume Flavors Fragrances Flavors
